USP Ephedra Review Scheduled For July; RAND Report Slated For Early Fall
This article was originally published in The Tan Sheet
The U.S. Pharmacopeia will discuss standard-setting issues related to the supplement ingredient ephedra during an internal meeting July 17
You may also be interested in...
An FDA task force will review the 13,000 ephedrine alkaloid patient complaint records Metabolife is releasing in response to publicity surrounding a criminal investigation into whether the company lied about its knowledge of adverse events
The National Toxicology Program is asking for toxicology data on ephedrine alkaloid dietary supplements by Aug. 12
The U.S. Pharmacopeia's final monograph on saw palmetto lists 10 published studies on the ingredient that met the USP quality standard of Level II or higher, under the organization's new criteria for evidence submission for botanicals.